摘要
目的观察替吉奥单药治疗老年晚期乳腺癌的疗效与安全性。方法回顾性分析老年晚期乳腺癌患者65例,研究组32例(S组):替吉奥40～60 mg(<1.25 m^2,40mg;1.25～1.5 m^2,50mg;>1.5 m^2,60 mg),于早、晚饭后口服,连服14天,21天重复。对照组33例(X组):卡培他滨每日2000mg/m^2,分2次,连服14天,21天重复,至少2周期后评价疗效。结果 65例患者均可评价疗效,S组、X组有效率(RR)分别为31.3%(10/32)、27.3%(9/33),疾病控制率(DCR)分别为78.1%(25/32)、69.7%(23/33),中位疾病进展时间(TTP)分别为7.5、7.0月,中位总生存时间(OS)分别为17.3、15.2月,两组比较差异无统计学意义(P>0.05)。研究组与对照组常见的不良反应为骨髓抑制、胃肠道反应、口角炎、乏力,多见Ⅰ～Ⅱ度,可耐受,两组差异无统计学意义;对照组手足综合征明显高于研究组,差异有统计学意义(P=0.000)。结论替吉奥单药治疗老年乳腺癌疗效肯定,耐受性好于卡培他滨,值得临床进一步研究、推广。
Objective To evaluate the efficacy and safety of S-1 monotherapy in elderly patients with advanced breast cancer. Methods Retrospectively analysis sixty-five elderly patients with advanced breast cancer. The study group（S group,n=32）：S-1：40-60 mg（〈1.25 m^2,40 mg; 1.25-1.5 m^2,50 mg;〉1.5 m^2,60 mg, twice/day, oral administration,d1-d14, three weeks was a cycle. The control group（X group,n=33）： Capecitabine ：2 000 mg/（m^2·d）, separated to twice, d1-d14, three weeks was a cycle.The efficacy and toxicity were evaluated by WHO standards after 2-cycle treatment.Results The efficacy and toxicity could be evaluated in the all 65 patients,the RR of S group and X group was 31.3%（10/32）,27.3%（9/33）,the DCR was 78.1%（25/32）,69.7%（23/33） , the median TTP was 7.5 ,7.0 months, the OS was 17.3,15.2 months . There was no significant difference（P〉0.05）.The most common toxicities of the two groups were hematological,digestive toxic reactions, stomatitis and feeble,mainly 1-2 degree,and could be well tolerated.The Hand-foot syndrome rate of X group exceeded the S group（P=0.000）. Conclusion The efficacy of S-1 for elderly patients with advanced breast cancer is significant with well-tolerated toxicity better than Capecitabine,and worth to further study and popularize.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2013年第5期481-484,共4页
Cancer Research on Prevention and Treatment
